Sun Lei, Guo Ren-Feng, Gao Hongwei, Sarma J Vidya, Zetoune Firas S, Ward Peter A
Department of Pathology, University of Michigan Medical School, 1301 Catherine Rd., Ann Arbor, MI 48109-5602, USA.
FASEB J. 2009 Nov;23(11):3808-18. doi: 10.1096/fj.09-133694. Epub 2009 Jul 20.
Acute lung injury (ALI) in mouse lung occurs after distal airway deposition of IgG immune complexes (IgGICs), resulting in a breakdown of the vascular-airway barrier, causing intrapulmonary edema, hemorrhage, and accumulation of neutrophils [polymorphonuclear leukocytes (PMNs)] in the alveolar compartment, these changes being complement (C5a) and C5a receptor (C5aR) dependent. In this ALI model, C5aR expression (protein) was found to occur on upper (bronchial) and lower (alveolar) airway epithelial cells. An adenovirus construct (siRNA) was used to silence mRNA for C5aR in the lung. Under such conditions, C5aR protein was markedly reduced on lung epithelial cells, resulting in much reduced leakage of albumin into the lung, diminished buildup of PMNs, and lower levels of proinflammatory mediators in bronchoalveolar lavage fluids. These studies indicate that bronchial and alveolar epithelial cell C5aR is up-regulated and greatly contributes to inflammation and injury in the lung. The use of siRNA administered into the airways avoids systemic suppression of C5aR, which might compromise innate immunity. It is possible that such an intervention might be employed in humans with ALI or acute respiratory distress syndrome as well as in upper-airway inflammatory diseases, such as chronic obstructive pulmonary disease and asthma, where there is evidence for complement activation and buildup of PMNs.
在小鼠肺部,IgG免疫复合物(IgGICs)经远端气道沉积后会引发急性肺损伤(ALI),导致血管-气道屏障破坏,引起肺内水肿、出血以及中性粒细胞[多形核白细胞(PMN)]在肺泡腔的积聚,这些变化依赖补体(C5a)和C5a受体(C5aR)。在这个ALI模型中,发现C5aR表达(蛋白质)出现在上呼吸道(支气管)和下呼吸道(肺泡)的上皮细胞上。一种腺病毒构建体(siRNA)被用于使肺内C5aR的mRNA沉默。在这种情况下,肺上皮细胞上的C5aR蛋白显著减少,导致白蛋白漏入肺内的情况大幅减少,PMN的积聚减少,支气管肺泡灌洗液中促炎介质水平降低。这些研究表明,支气管和肺泡上皮细胞的C5aR被上调,并在很大程度上导致肺部炎症和损伤。将siRNA经气道给药可避免对C5aR的全身抑制,而全身抑制可能会损害固有免疫。这种干预措施有可能应用于患有ALI或急性呼吸窘迫综合征的人类患者,以及上呼吸道炎症性疾病,如慢性阻塞性肺疾病和哮喘,这些疾病存在补体激活和PMN积聚的证据。